MARC details
000 -LEADER |
fixed length control field |
03093nam a22005657a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
180508s20182018 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
0306-9877 |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1016/j.mehy.2018.02.036 [doi] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
S0306-9877(17)31218-5 [pii] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
29602462 |
245 ## - TITLE STATEMENT |
Title |
Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy. |
251 ## - Source |
Source |
Medical Hypotheses. 114:40-44, 2018 May |
252 ## - Abbreviated Source |
Abbreviated source |
Med Hypotheses. 114:40-44, 2018 May |
253 ## - Journal Name |
Journal name |
Medical hypotheses |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2018 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2018 |
266 ## - Date added to catalog |
Date added to catalog |
2018-05-08 |
520 ## - SUMMARY, ETC. |
Abstract |
Copyright (c) 2018 Elsevier Ltd. All rights reserved. |
520 ## - SUMMARY, ETC. |
Abstract |
The concurrence of atrial fibrillation and acute coronary syndrome poses a conundrum in the antithrombotic management as intensification of anticoagulation or antiplatelet therapy inevitably comes at the price of an increased bleeding risk. Various antithrombotic combinations have been attempted to prevent the recurrent cardiovascular events, however, there has been limited success in effective risk reduction for this high risk population. Given the overarching effect of interleukin 1beta-driven inflammation on the arrhythmogenesis, thrombogenesis, and hypercoagulability, we hypothesize that the triple-pathway strategy (i.e., incorporating antiinflammatory therapy into anticoagulant and antiplatelet therapy) would grant incremental cardiovascular benefits for atrial fibrillation patients with coexisting acute coronary syndrome and stent placement. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Acute Coronary Syndrome/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Anti-Inflammatory Agents/ad [Administration & Dosage] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Atrial Fibrillation/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Fibrinolytic Agents/ad [Administration & Dosage] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Acute Coronary Syndrome/co [Complications] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Anticoagulants/ae [Adverse Effects] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Arrhythmias, Cardiac/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Aspirin/tu [Therapeutic Use] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Atrial Fibrillation/co [Complications] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cardiovascular System |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Comorbidity |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Drug Therapy, Combination |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Hemorrhage/ci [Chemically Induced] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Interleukin-1beta/me [Metabolism] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Models, Theoretical |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Platelet Aggregation Inhibitors |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Randomized Controlled Trials as Topic |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Stents |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Stroke/co [Complications] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Warfarin/tu [Therapeutic Use] |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Union Memorial Hospital |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Jamil, Umer |
790 ## - Authors |
All authors |
Balouch MA, Chi G, Jafarizade M, Jamil A, Jamil U, Kalayci A, Karimi Z, Kumar S, Marszalek J, Pahlavani S, Radulovic M, Shaukat H |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1016/j.mehy.2018.02.036">https://dx.doi.org/10.1016/j.mehy.2018.02.036</a> |
Public note |
https://dx.doi.org/10.1016/j.mehy.2018.02.036 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |